Loading company financials…
Nasdaq · Biological Products, (No Diagnostic Substances) · CIK 0000882095
$151.00
+3.65% · delayed 15 min
$187.38B market value
What this company does
GILEAD SCIENCES develops and makes medicines. It took in $29.44B last year, which makes it a large company. Of every dollar it sells, about 29 cents is left as profit.
Financial health
Strong finances across the board.
From GILEAD SCIENCES, INC.'s FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Improved: +1672.9%
$480.0M to $8.51B
Improved: +27.2 pts
1.7% to 28.9%
Deteriorated: -8.2%
$10.30B to
It makes a profit rather than burning through money.
$8.51B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$10.02B cash from operations
Its debt is small next to the cash the business produces.
about 1.7 years of cash flow to clear
It passes almost every standard check of financial strength.
Piotroski 8/9
Nothing in the filings stands out as a concern.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 7% a year for the next 10 years. Over the last 10 years it shrank by about 7% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 29 cents of every dollar of sales as profit, earning $8.51B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Whether the dividend is covered by what the business actually earns
It pays out 47 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 40% of the cash its operations generated. It has paid in each of the last 11 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $8.51B and generated $10.02B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Quarterly report(10-Q) | 2026-08-06 | 2026-06-30 |
| Major event announcement(8-K) | 2026-08-04 | 2026-08-04 |
Financial figures are from GILD's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
4.61
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.45
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: -11.1%
$24.90B to $22.13B
Deteriorated: -24.3%
$9.99B to $7.56B
Changed: +7.6%
$523.0M to $563.0M
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 4% and 9%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Barely. Sales were roughly flat, up 2.4%.
No. At its current cash flow it could clear its debt in about 1.7 years. For every $1 it owes, it owns $1.63 in assets.
Around average. Investors pay $22.0 for every $1 of yearly profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-05-20 | 2026-05-14 |
| Quarterly report(10-Q) | 2026-05-07 | 2026-03-31 |
| Major event announcement(8-K) | 2026-05-07 | 2026-05-07 |
| Major event announcement(8-K) | 2026-05-04 | 2026-04-30 |
| Major event announcement(8-K) | 2026-04-28 | 2026-04-28 |
| Shareholder voting information(DEF 14A) | 2026-03-20 | 2026-04-30 |
| Annual report(10-K) | 2026-02-24 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-23 | 2026-02-22 |
| Major event announcement(8-K) | 2026-02-10 | 2026-02-10 |
| Major event announcement(8-K) | 2025-11-19 | 2025-11-15 |
| Quarterly report(10-Q) | 2025-11-07 | 2025-09-30 |
| Major event announcement(8-K) | 2025-10-30 | 2025-10-30 |
| Major event announcement(8-K) | 2025-10-06 | 2025-10-06 |
| Major event announcement(8-K) | 2025-08-14 | 2025-08-10 |
| Quarterly report(10-Q) | 2025-08-07 | 2025-06-30 |
| Major event announcement(8-K) | 2025-08-07 | 2025-08-07 |
| Major event announcement(8-K) | 2025-08-04 | 2025-07-30 |
| Major event announcement(8-K) | 2025-05-08 | 2025-05-07 |
Coverage from the last 30 days
Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals
Yahoo Finance ·
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Yahoo Finance ·
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?
Yahoo Finance ·
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Yahoo Finance ·
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
Yahoo Finance ·
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Yahoo Finance ·
Is Gilead Sciences Stock Outperforming the S&P 500?
Yahoo Finance ·
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Yahoo Finance ·
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Yahoo Finance ·
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
Yahoo Finance ·
Gilead (GILD) Stock Looks Undervalued After A 147% Five Year Run
Yahoo Finance ·
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Yahoo Finance ·
Primary sources and further research